Pasar al contenido principal

LA INHIBICION DE MIR122 COMO EVENTO PRECOZ RN RL DESARROLLO DE CARCINOMA HEPATOCELULAR EN PACIENTES INFECTADOS POR EL VIRUS DE LA HEPATITIS C. PAPEL DE MIR122 EN EL SISTEMA INMUNITARIO

PI18/00768

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Centro realización INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Trial, Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)

  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Matilla, Ana
  • Lledó-Navarro, José Luis|||0000-0001-7973-3503
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Iñarrairaegui, Mercedes|||0000-0001-9180-4693
  • Perelló, Christie|||0000-0003-0234-2330
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Llarch, Neus|||0000-0003-3209-0453
  • Márquez, Laura
  • Guerrero, Antonio
  • Iserte, Gemma|||0000-0003-3908-8743
  • Castaño-García, Andrés|||0000-0002-7921-9026
  • Carrión, Laura
  • Fortuny, Marta
  • Rimola, Jordi|||0000-0002-1814-4198
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Domenech, Gema
  • Torres, Ferran|||0000-0002-7355-7913
  • Ríos, José|||0000-0002-0716-8784
  • Boix, Loreto|||0000-0002-6015-3901
  • Samper, Esther
  • Kateb, Àngels
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
BACKGROUND & AIMS: Highly effective second-line treatments for hepatocellular carcinoma remain an unmet need. The GOING investigator-initiated Phase I/IIa trial evaluated regorafenib plus nivolumab (add-on) in patients who progressed on sorafenib (Cohort-A) or discontinued atezolizumab-bevacizumab (Cohort-B). METHODS: Patients received regorafenib for two 28-day cycles, adding nivolumab in cycle 3, until unacceptable adverse events, symptomatic progression, withdrawal or death. Primary endpoint was safety. Secondary endpoints included overall survival, time to progression, post-progression survival, objective response rate and incidence of new-extrahepatic-spread. RESULTS: Of 85 patients screened, 67 were enrolled (75.5% BCLC-C). All experienced adverse events and 9% led to discontinuation. Severe treatment-related adverse events occurred in 28.4% overall, 32.1% in Cohort-A, and 14.3% in Cohort-B. Median overall survival was 20.0 (95% CI 11-37) months, with 40.6% survival at 36 months. In Cohort-A, median overall survival was 25 (95% CI 14-39) months with 45% survival at 36 months, while Cohort-B median overall survival was 8 (95% CI 4-NE) months with 28.6% survival at 24 months. Objective response rate was 16.4%; median time to progression and post-progression survival were 5 (95% CI 4-9) months and 14 (95% CI 8-33) months. Intrahepatic growth was the most common progression pattern, followed by new-extrahepatic-spread. CONCLUSIONS: The add-on strategy of regorafenib plus nivolumab in second-line had manageable safety and significant clinical activity with a noteworthy median overall survival of 20 months. Among those progressing on sorafenib, 45% were alive at 3 years. These findings support further evaluation with mechanism-guided trials after progression on immunotherapy. TRIAL REGISTRATION: EudraCT number: 2019-003108-10; https://www.clinicaltrialsregister.eu.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Sapena, Victor|||0000-0003-4379-6486
  • Boix, Loreto|||0000-0002-6015-3901
  • Torres, Ferran|||0000-0002-7355-7913
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Guedes, Cassia
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darnell, Anna
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Rimola, Jordi|||0000-0002-1814-4198
  • Forner, Alejandro|||0000-0002-9014-4950
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Bruix, Jordi|||0000-0002-9826-0753
  • Reig, María|||0000-0002-5711-9534
Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outcome of liver cancer patients with SARS-CoV-2 infection, An International, Multicentre, Cohort Study

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Ríos, José|||0000-0002-0716-8784
  • Bouattour, Mohamed|||0000-0002-3919-4135
  • El-Kassas, Mohamed|||0000-0002-3396-6894
  • Leal, Cassia R. G.
  • Mocan, Tudor|||0000-0001-7785-6403
  • Nault, Jean-Charles|||0000-0002-4875-9353
  • Alves, Rogerio C. P.
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • García-Juárez, Ignacio|||0000-0003-2400-1887
  • Pinato, David James|||0000-0002-3529-0103
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Alvares-da-Silva, Mario R.|||0000-0002-5001-246X
  • Bandi, Juan C.|||0000-0001-9733-1938
  • Rimassa, Lorenza|||0000-0001-9957-3615
  • Lozano, Mar|||0000-0001-7099-0810
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Tacke, Frank|||0000-0001-6206-0226
  • Sala, Margarita
  • Anders, María|||0000-0002-2238-5322
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Piñero, Federico
  • França, Alex
  • Guarino, Maria|||0000-0002-0460-4122
  • Elvevi, Alessandra
  • Cabibbo, Giuseppe|||0000-0002-0946-3859
  • Peck-Radosavljevic, Markus|||0000-0002-0597-2728
  • Rojas, Ángela|||0000-0003-0853-4800
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Braconi, Chiara|||0000-0003-4835-1259
  • Pascual, Sonia|||0000-0002-4265-5019
  • Perelló, Christie|||0000-0003-0234-2330
  • Mello, Vivianne
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Acevedo, Juan|||0000-0003-4507-2422
  • Villani, Rosanna|||0000-0001-9875-019X
  • Hollande, Clemence|||0000-0002-2287-0635
  • Vilgrain, Valérie
  • Tawheed, Ahmed|||0000-0002-9382-8733
  • Ferguson Theodoro, Carmem|||0000-0001-6605-1060
  • Sparchez, Zeno
  • Blaise, Lorraine
  • Viera-Alves, Daniele E.
  • Watson, Robyn
  • Carrilho, Flair J.
  • Moctezuma-Velázquez, Carlos|||0000-0003-2367-2742
  • D'Alessio, Antonio
  • Iavarone, Massimo|||0000-0003-3493-6504
  • Reig, María|||0000-0002-5711-9534
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p =.0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p =.5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p =.0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication, A Population-Based Cohort Study

  • Ríos, José|||0000-0002-0716-8784
  • Sapena, Victor|||0000-0003-4379-6486
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bruix, Jordi|||0000-0002-9826-0753
  • Forns, Xavier|||0000-0002-8188-1764
  • Morros, Rosa|||0000-0001-6752-8748
  • Reig, María|||0000-0002-5711-9534
  • Torres, Ferran|||0000-0002-7355-7913
  • Pontes García, Caridad|||0000-0002-3274-6048
Background and Objectives: Direct-acting antivirals (DAAs) offer a high rate of hepatitis C virus (HCV) eradication. However, concerns on the risk of cancer after HCV eradication remain. Our study aimed at quantifying the incidence of cancer in patients treated with anti-HCV therapies in Catalonia (Spain) and their matched controls. Methods: This was a population-based study using real-world data from the public healthcare system of Catalonia between 2012 and 2016. Propensity score matching was performed in patients with HCV infection treated with interferon-based therapy (IFN), sequential IFN and DAA (IFN+DAA), and DAA only (DAA) with concurrent controls. We estimated the annual incidence of overall cancer, hepatocellular carcinoma, and non-liver cancer of HCV-treated patients and their corresponding rate ratios. Results: The study included 11,656 HCV-treated patients and 49,545 controls. We found statistically significant increases in the rate of overall cancer for IFN+DAA-treated (rate ratio [RR] 1.77, 95% confidence interval [CI] 1.27-2.46) and DAA-treated patients (RR 1.90, 95% CI 1.66-2.19) and in the rate of HCC for IFN-treated (RR 1.50, 95% CI 1.02-2.22), IFN+DAA-treated (RR 3.89, 95% CI 2.26-6.69), and DAA-treated patients (RR 6.45, 95% CI 4.90-8.49) compared with their corresponding controls. Moreover, DAA-treated patients with cirrhosis showed an increased rate of overall cancer versus those without cirrhosis (RR 1.92, 95% CI 1.51-2.44). Conclusions: Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.